Skip to content
E3 · Other / exploratoryReviewPEM unclearNarrative reviewPeer-reviewed
Standard · 3 min

Hypothalamic-Pituitary-Adrenal Hypofunction in Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS) as a Consequence of Activated Immune-Inflammatory and Oxidative and Nitrosative Pathways.

Morris, Gerwyn, Anderson, George, Maes, Michael

Molecular neurobiology2017DOIPubMed

Design
Narrative review
Participants
Not reported
PEM required
Unclear
Case definition
Not stated in the abstract

Quick Summary

This review examines why people with ME/CFS often have low cortisol levels (a stress hormone). The researchers found that the problem likely starts with an overactive immune system producing excessive inflammatory markers, which then damages the body's stress-hormone system. This is important because it suggests the low cortisol is a consequence of the disease, not its cause.

Why It Matters

Understanding whether HPA axis dysfunction causes or results from immune activation has critical implications for treatment strategies. If immune activation drives HPA suppression, therapeutic approaches should target immune pathways rather than attempting hormone replacement. This reframing could redirect research and clinical practice toward more mechanistically appropriate interventions.

Observed Findings

What the study reports it measured.

  • Elevated tumor necrosis factor-α (TNF-α) levels in ME/CFS patients
  • Dysregulated T regulatory responses with increased interleukin-10 (IL-10) and transforming growth factor-β (TGF-β)
  • Elevated nitric oxide levels
  • Lowered baseline glucocorticoid and ACTH levels
  • Viral and bacterial-mediated immune activation in disease presentation

Inferred Conclusions

What the authors interpret from those results.

  • Immune-inflammatory and O&NS pathway activation is likely primary and causative rather than secondary to HPA axis hypofunction
  • HPA axis hypoactivity in ME/CFS represents a consequence of chronic immune activation, not its etiology
  • Mechanisms involving cytokine dysregulation and oxidative stress may explain how immune pathways suppress HPA function
  • Therapeutic strategies should target activated immune pathways rather than attempting HPA axis correction alone

Remaining Questions

  • What initiates the initial immune activation that drives HPA suppression—viral infection, post-infectious sequelae, genetic predisposition, or environmental trigger?
  • Do all ME/CFS patients follow the same pathophysiologic pathway, or are there mechanistically distinct disease subtypes?
  • How do specific cytokines and O&NS markers directly interfere with hypothalamic-pituitary function at the molecular level?
  • Which interventions targeting immune pathways would most effectively restore HPA function and improve clinical outcomes?

What This Study Does Not Prove

This review does not establish definitive causal mechanisms—it interprets correlational data from multiple studies. It does not prove that immune pathways are the sole cause of HPA dysfunction, nor does it demonstrate whether these pathways are primary disease drivers or secondary amplifiers. Individual patient heterogeneity may mean different subgroups have different underlying mechanisms.

Explore further

About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →

Cite this study

The first block is for the primary paper and is the citation you should use in research work. The atlas-snapshot line only applies if you are specifically referring to this atlas’s reading of the paper on the date shown.

Primary citation

Morris, Gerwyn, Anderson, George, & Maes, Michael (2017). Hypothalamic-Pituitary-Adrenal Hypofunction in Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS) as a Consequence of Activated Immune-Inflammatory and Oxidative and Nitrosative Pathways.. Molecular neurobiology. https://doi.org/10.1007/s12035-016-0170-2

BibTeX

@article{mecfsatlas-morris-2017-hypothalamic-pituitary,
  author  = {Morris, Gerwyn and Anderson, George and Maes, Michael},
  title   = {Hypothalamic-Pituitary-Adrenal Hypofunction in Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS) as a Consequence of Activated Immune-Inflammatory and Oxidative and Nitrosative Pathways.},
  journal = {Molecular neurobiology},
  year    = {2017},
  doi     = {10.1007/s12035-016-0170-2},
  note    = {PubMed: 27766535},
  url     = {https://www.mecfsatlas.com/evidence/morris-2017-hypothalamic-pituitary},
}

Atlas snapshot reference

ME/CFS Atlas. Generator v1 / Scanner v1.4 / policy v0.1. Accessed 2026-11-15. https://www.mecfsatlas.com/evidence/morris-2017-hypothalamic-pituitary

Contribute

Private, reviewed by a human. Not a public comment thread.